SAN FRANCISCO and DUBAI, United Arab Emirates, Dec. 2, 2015 (GLOBE NEWSWIRE) -- BioQ Pharma Incorporated, a specialty pharmaceutical company focused on the development and commercialization of large volume ready-to-use infusible pharmaceuticals, and Lunatus, a company focused on building and developing profitable pharmaceutical brands in Arabian Gulf and Middle East markets, today announced the signing of a strategic distribution, supply and development agreement for the registration and commercialization of BioQ Pharma's ropivacaine and propofol infusion pharmaceutical products in Saudi Arabia, the United Arab Emirates, Qatar and Kuwait.
BioQ Pharma's unit-dose infusible pharmaceuticals have been developed as ready-to-use presentations in which the drugs and administration systems are self-contained and delivered at the point of care. The ropivacaine pharmaceutical is pre-filled with 0.2% ropivacaine and intended to provide a safer, more efficient continuous-infusion post-operative pain solution. BioQ Pharma's propofol infusion pharmaceutical is prefilled 1% propofol, and features both programmable flow and bolus capabilities.
Josh Kriesel, President and CEO of BioQ Pharma, remarked, "We are pleased with the opportunity to partner with Lunatus as we pursue our goal of setting a new standard of care in the presentation and administration of infusible pharmaceuticals throughout the world. Lunatus' proven marketing team will be essential in introducing BioQ Pharma's proprietary unit-dose, large volume infusion pharmaceuticals to the MENA region. We are extremely excited to be expanding our worldwide network through such a distinguished partner."
Dr. Lina Kouatly, Managing Director of Lunatus, noted, "We are thrilled to collaborate with BioQ Pharma as we advance towards introducing two unit-dose infusion pharmaceuticals to the MENA region. BioQ Pharma's innovative infusion pharmaceutical products offer a highly differentiated mode of delivering infusible pharmaceuticals to patients. We see significant utility in BioQ's ready-to-use pharmaceuticals and believe they will remove much of the burden and overhead associated with the time consuming steps normally associated with drug infusions."
About BioQ Pharma
BioQ Pharma Incorporated is a privately held specialty pharmaceutical company focused on developing and commercializing ready-to-use infusible pharmaceuticals. The Company's infusion platform is intended to address some of the most pressing unmet needs in drug infusion today: cost, medication error, sterility, efficiency, and patient quality of life. BioQ Pharma's objective is to set a new standard of care in the presentation and administration of infusible pharmaceuticals via the Company's proprietary unit-dose infusion systems that can be deployed quickly and conveniently at the point of care with one touch. The Company is ISO13485 certified. BioQ Pharma's existing commercial collaborators and strategic partners include Novartis' Sandoz unit, Cipla, Lee's Pharm and West Pharmaceutical Services.
Since its inception in 2003, Lunatus has established a successful track record in introducing, building and developing profitable brands in the fields of pharmaceutical, RX & OTC, aesthetic medicine & skin care, consumer health and medical equipment for international healthcare companies in the Arabian Gulf and Middle East markets. The Company's mission is to provide value added marketing and operational services tailored to the versatility of the region. Lunatus partners with wide array of healthcare companies and corresponding brands including Valeant, Mylan, Merz Aesthetics, Omega Pharma, SoftFil, Opko Lab, Lumenis, BSN Medical, Ferris MFG. Corp. and IPRAD Laboratories. For more details about Lunatus Marketing and Consultancy please visit www.lunatus-me.com or email email@example.com.
Forward Looking Statements (BioQ Pharma Inc.)
This press release may contain forward-looking information about BioQ Pharma Incorporated (the "Company"). Forward-looking statements are statements that are not historical facts. Words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "strong," "upcoming," "prepared" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding our ability to successfully develop and commercialize our therapeutic products; our ability to expand our long-term business opportunities; and our future performance, as well as the performance of our commercial and manufacturing partners.
All such statements are subject to certain risks and uncertainties, many of which are difficult to predict and some of which are beyond the Company's control, that could cause actual results to differ materially from those expressed in, or implied by, the forward-looking information and statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.
CONTACT: BioQuiddity Contact Information: Josh Kriesel President and CEO 415-336-6496 Ron Pauli Chief Financial Officer 415-889-7707 Lunatus Contact Information: Dr Lina Kouatly Managing Director Lina@lunatus-me.com T: +971 4 3994755 Noura Ghanem Marketing Manager Noura.firstname.lastname@example.org T: +971 4 3994755 Media: Stephanie Carrington Integrated Corporate Relations, Inc (ICR) email@example.com 646-277-1282
Source: BioQ Pharma